Medici List crest

Twist Bioscience Corp

CIK: 15812802 Annual ReportsLatest: 2026-11-16
Revenue: $459,400,000Net Income: -$130,202,000Source 10-K
Disclaimer: AI-assisted summary of SEC Form 10-K filings. Not official company content and not investment, legal, accounting, or tax advice. See full disclaimer here.

10-K / November 16, 2026

Revenue:$459,400,000
Income:-$130,202,000

10-K / November 18, 2024

Revenue:$313,000,000
Income:-$208,700,000

10-K / November 16, 2026

Twist Bioscience Corporation

Overview

Twist Bioscience provides customizable solutions across the biological continuum to help customers read, write, and innovate in biology. Its core capability is a proprietary silicon-based DNA synthesis platform that writes DNA directly on a silicon chip. The platform miniaturizes traditional chemical DNA synthesis to write over 1,000,000 oligonucleotides up to 500 bases per chip on a chip about the size of a large mobile phone, reducing chemical usage by 99.8% versus plate-based synthesis. The platform is combined with software and scalable infrastructure to deliver integrated, high-throughput, cost-efficient DNA writing and enable rapid design–build–test cycles.

Product groups and solutions

  • DNA Synthesis and Protein Solutions (merged in fiscal 2026)
    • End-to-end DNA synthesis and protein-related services for therapeutic drug discovery.
    • Capabilities include DNA synthesis, protein expression, antibody characterization, and biologics discovery solutions.
    • Modern antibody discovery workflows and AI-assisted design and data generation for drug discovery.
    • Enzyme engineering, nucleic acid therapeutics workflows, and related data generation and characterization services.
  • NGS Applications (formerly NGS tools)
    • Tools used between sample and sequencer, including target enrichment panels and library preparation kits.
    • Supports sequencing workflows across multiple platforms with products that improve sequencing accuracy, reduce costs, and enable rapid deployment (examples include the FastHyb workflow and methylation detection kits).
  • Shared platform and workflow
    • The same silicon-based DNA writing platform underpins both product groups, enabling cross-sell opportunities and improved unit economics through higher utilization.

Key capabilities and competitive position

  • Silicon-based platform that writes millions of DNA sequences in parallel with high uniformity and accuracy.
  • High-throughput, scalable DNA synthesis and related products focused on speed, precision, automation, and cost reduction.
  • Connected workflow from DNA synthesis to protein production and data generation, supporting in vitro, in vivo, and in silico discovery.
  • Integrated AI-guided design with synthesis and protein workflows is a growing component of demand.

Market and customers

  • Global customer base of approximately 4,100 customers across therapeutics, diagnostics, academic and government, industry and applied, and other life sciences segments.
  • Employee count: 1,080 total as of September 30, 2026.

Financials (fiscal year 2026)

  • Revenue: $459.4 million
    • Therapeutics: $162.3 million
    • Diagnostics: $164.3 million
    • Academic research and government: $56.6 million
    • Global supply partners: $52.0 million
    • Industry and applied: $24.2 million
  • Revenue reflects contributions from both DNA Synthesis and Protein Solutions and NGS Applications.
  • As of May 2026, approximately $1.0 billion of the DNA Synthesis and Protein Solutions SAM was attributed to AI-enabled drug discovery (split evenly between antibody discovery services and protein expression).

Headcount and organization

  • Total employees: 1,080 (as of September 30, 2026)
    • Research and development: 130
    • Marketing, sales and customer support: 321
    • General and administrative: 198
    • Operations and manufacturing (DNA Synthesis/Protein Solutions and NGS Applications): 431
  • Sales channels include a worldwide direct sales force, Europe/Asia-based consultants, and an e-commerce platform that supports on-demand design, validation, ordering, real-time quotes, and order tracking.

Manufacturing and facilities

  • Primary manufacturing sites:
    • Wilsonville, Oregon: primary site for DNA Synthesis and Protein Solutions.
    • South San Francisco, California: primary site for NGS Applications.
  • Manufacturing is highly automated and designed for 24/7 gene synthesis operations.
  • Some sub-assemblies are outsourced to third-party manufacturers.
  • Certifications:
    • ISO 13485:2016 Quality Management System for RUO and Precision Dx products (South San Francisco and Wilsonville).
    • ISO/IEC 27001:2022 information security management system certification.

Intellectual property

  • Portfolio includes over 200 issued or allowed patents and more than 230 pending patent applications (as of September 30, 2026).
  • Focus on patents related to DNA synthesis, NGS, and antibody libraries, with preferential licensing where required.

Regulatory and compliance

  • RUO (Research Use Only) products predominate in many markets; certain IVD products are CE-marked under IVDR in Europe.
  • U.S. FDA regulatory framework for medical devices applies to IVDs; RUO labeling does not exempt diagnostic use from potential future regulatory requirements.
  • EU IVDR compliance for select products; IVDR-compliant Precision Dx products for whole exome sequencing released in February 2024.
  • Adheres to export controls and the Framework for Nucleic Acid Synthesis Screening (OSTP) with public attestations of compliance; regulatory developments are ongoing at federal and international levels.
  • Federal Select Agent Program (FSAP) considerations: the company states it generally does not work with select agents or toxins.

Growth strategy and corporate initiatives

  • Objective: be a leading provider of customizable solutions across the biological continuum, using the silicon platform to add products, applications, and solutions.
  • Growth levers:
    • Expand protein production, characterization, and data generation to support traditional and AI-enabled therapeutics discovery.
    • Maintain and expand NGS sample prep and target enrichment offerings and grow with clinical and commercial NGS use.
    • Introduce new products using the existing platform, including nucleic acid therapeutics.
    • Improve efficiency and capacity through automation and continuous process improvements.
    • Expand global presence via direct, digital, and partner/distributor channels.

Notes on profitability

  • The company has incurred net losses in every period to date and may continue to experience losses as it develops its business.

If you want, I can condense this into a one-page executive summary or extract specific figures (for example, revenue by product line or headcount by function) for a quick briefing.